The World Health Organisation (WHO) has announced that it has decided to stop the hydroxychloroquine (HCQ) arm of the Solidarity Trial to find an effective COVID-19 treatment.
In a statement, WHO said the trial’s Executive Group and principal investigators made the decision based on evidence from the Solidarity Trial, UK’s Recovery trial and a Cochrane review of other evidence on hydroxychloroquine.
“Data frоm Sоlidаritу (inсluding thе Frеnсh Diѕсоvеrу triаl dаtа) аnd thе recently аnnоunсеd rеѕultѕ frоm thе UKѕ Recovery triаl both ѕhоwеd thаt hydroxychloroquine dоеѕ not rеѕult in thе rеduсtiоn оf mоrtаlitу оf hоѕрitаliѕеd COVID-19 patients, whеn соmраrеd with standard of саrе,” WHO ѕtаtеd.
With this development, WHO said Investigators will not randomize further patients to hydroxychloroquine and patients who have already started hydroxychloroquine but who have not yet finished their course in the trial may complete their course or stop at the discretion of the supervising physician.
“This decision applies only to the conduct of the Solidarity trial and does not apply to the use or evaluation of hydroxychloroquine in pre- or post-exposure prophylaxis in patients exposed to COVID-19,” WHO stated.